Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
1,19 USD | +3,48% | +4,39% | +50,06% |
Attività
Numero di dipendenti: 449
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Novel Cell Therapies
100,0
%
| 27 | 100,0 % | 60 | 100,0 % | +122,05% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United Kingdom
100,0
%
| 27 | 100,0 % | 60 | 100,0 % | +122,05% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Founder | 57 | 01/01/08 | |
Adrian Rawcliffe
CEO | Chief Executive Officer | 52 | 01/03/15 |
Gavin Wood
DFI | Director of Finance/CFO | 54 | 01/04/20 |
Joanna Brewer
CTO | Chief Tech/Sci/R&D Officer | 47 | 01/01/09 |
Elliot Norry
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/07/15 |
William Bertrand
COO | Chief Operating Officer | 59 | 15/03/17 |
Juli P. Miller
IRC | Investor Relations Contact | - | 01/08/16 |
Sharp Kerry
LAW | General Counsel | - | 01/10/15 |
Phil Bassett
PRN | Corporate Officer/Principal | - | - |
John Lunger
PRN | Corporate Officer/Principal | 55 | 01/03/17 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | 01/11 |
Andrew Allen
BRD | Director/Board Member | 57 | 01/06/23 |
David Mott
CHM | Chairman | 58 | 01/09/14 |
Adrian Rawcliffe
CEO | Chief Executive Officer | 52 | 01/03/15 |
Ali Behbahani
BRD | Director/Board Member | 47 | 01/09/14 |
Garry Menzel
BRD | Director/Board Member | 59 | 01/06/23 |
John Furey
BRD | Director/Board Member | 59 | 05/07/18 |
Lawrence Alleva
BRD | Director/Board Member | 74 | 01/03/15 |
Priti Hegde
BRD | Director/Board Member | 52 | 01/06/23 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 1 480 950 456 | 223 044 163 ( 15,06 %) | 0 | 15,06 % |
Coordinate società
Adaptimmune Therapeutics Plc
60 Jubilee Avenue Milton Park
OX14 4RX, Abingdon
+44 12 3543 0000
http://www.adaptimmune.comSettore
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+50,06% | 294 Mln | |
-3,46% | 102 Mrd | |
+1,41% | 96,29 Mrd | |
+2,13% | 22,18 Mrd | |
-15,84% | 21,2 Mrd | |
-9,21% | 18,31 Mrd | |
-39,98% | 17,38 Mrd | |
-14,65% | 16,36 Mrd | |
+4,39% | 13,97 Mrd | |
+31,35% | 12,17 Mrd |
- Borsa valori
- Azioni
- Azione ADAP
- Società Adaptimmune Therapeutics plc